Skip to main content
. Author manuscript; available in PMC: 2016 Dec 1.
Published in final edited form as: Mol Cancer Ther. 2015 Oct 5;14(12):2797–2804. doi: 10.1158/1535-7163.MCT-15-0291-T

Figure 2. Aptamer mediated DNA-PK silencing and IR sensitization.

Figure 2

A, LNCaP-MLuc cells treated with 400 nM A10-3-Con or A10-3-DNAPK, in the absence of transfection reagents, or transfected with 100 nM siDNAPK. Relative DNA-PK expression quantified by qRT-PCR. Mean ± SEM (n = 3). *P < 0.05, relative to A10-3-Con. B, DNA-PK protein quantification of the same treatments by Western blot. C, In vitro radiosensitization of LNCaP-MLuc cells treated with 400 nM A10-3-DNAPK or A10-3-Con, in the absence of transfection reagents, or transfected with 100 nM siDNAPK. Cells were irradiated 72 hours after treatment (0-6 Gy) and relative cell viability detected by secreted MLuc Activity. Percent cell viability relative to 0 Gy for each treatment. Mean ±SEM (n = 3) *P < 0.05 relative to A10-3-Con at each dose. D, Relative cell viability of treated cells quantified by CellTiter-blue assay. Percent cell viability relative to 0 Gy for each treatment. Mean ±SEM (n = 3). *P < 0.05 relative to A10-3-Con at each dose.